Premium
Effects of experimentally induced Pasteurella haemolytica infection in dairy calves on the pharmacokinetics of flumequine
Author(s) -
MEVIUS D. J.,
BREUKINK H. J.,
MIERT A. S. J. P. A. M.,
KESSELS B. G. F.,
JOBSE A. S.,
SMIT J. A. H.
Publication year - 1991
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1991.tb00820.x
Subject(s) - flumequine , pharmacokinetics , bioavailability , intramuscular injection , absorption (acoustics) , chemistry , pharmacology , medicine , microbiology and biotechnology , antibiotics , biology , ciprofloxacin , enrofloxacin , physics , acoustics
The effect of experimental Pasteurella haemolytica infection on the intravenous and intramuscular pharmacokinetics of flumequine was studied in dairy calves. The plasma concentration‐time curve of flumequine after intravenous injection of 5 mg/kg bodyweight flumequine of a 10% solution before and after experimental infection, was best described by a three‐compartment open model. After intramuscular injection of the same dosage rate of a 3% flumequine suspension it was best described by the one‐compartment open model with first‐order absorption. The experimental infection by intratracheal administration of infectious bovine rhinotracheitis (IBR)‐virus and 5 days later intrapulmonary administration of Pasteurella Iraemolylica produced a clear temperature rise and signs of disease expressed as Average Health Status. Subsequently, plasma Fe and Zn concentration decreased after infection. The distribution volumes V c , V d (area) and V d(ss) after infection (0.07± 0.04, 1.38 ± 0.36 and 0.50 ±0.11 1/kg, respectively) were smaller than those before infection, but the differences were not significant ( P ≤0.1). The intravenous AUC. was significantly increased (21.86 ± 3.51 to 33.85 ± 2.97 mg.h/I, P ≤ 0.01) and the total body clearance (Cl B ) significantly decreased (0.24 ± 0.02 to 0.15 ± 0.01, P ≤ 0.01) after infection. After intramuscular injection of flumequine at 5 mg/kg as a 3% suspension, only the bioavailability, F , was significantly decreased after infection (78.5 ± 14.3 to 59.7 ± 21.2%, P ≤ 0.02). However, this had no consequences for the dosage regimen used. The urine concentration ratio flumequine:7‐hydroxy‐flumequinerconjugated flumequine changed from 2:1:10 before infection to 6:1:15 after infection, which indicates that hydroxylation and glucuronidation as metabolic pathways for flumequine were decreased after Pasteurella sp. infection.